Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 10-Jun-24 4:19 PM View:  | Frieson Ron Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 69% 43.7K to 73.7K | |
| 10-Jun-24 4:19 PM View: | Gilman Steven C Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 34% 87.13K to 117.13K | |
| 10-Jun-24 4:20 PM View: | Wolf Myles Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 44% 67.68K to 97.68K | |
| 10-Jun-24 4:20 PM View: | Smith Cynthia Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 32% 95.23K to 125.23K | |
| 10-Jun-24 4:18 PM View: | Adams Adrian Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 22% 134.8K to 164.8K | |
| 10-Jun-24 4:19 PM View: | Rogers Michael W Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 31% 96.03K to 126.03K | |
| 10-Jun-24 4:18 PM View: | Zumwalt Leanne M Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-24 | Grant | 30,000 | -- | -- | 69% 43.7K to 73.7K | |
| 14-May-24 4:04 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 13-May-24 | Sale (Planned) | 34,840 | $1.26 | $43,898.40 | (5%) 706.93K to 672.09K | |
| 14-May-24 4:05 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 13-May-24 | Sale (Planned) | 12,016 | $1.26 | $15,140.20 | (2%) 663.26K to 651.24K | |
| 01-Mar-24 5:46 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 29-Feb-24 | Sale | 7,169 | $1.58 | $11,327.00 | (1%) 703.01K to 695.84K | |
| 01-Mar-24 5:48 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 29-Feb-24 | Sale | 5,974 | $1.58 | $9,438.92 | (< 1%) 669.23K to 663.26K | |
| 01-Mar-24 5:47 PM View: | Butler John P. CEO and President Director | Akebia Therapeutics, Inc. (AKBA) | 29-Feb-24 | Sale | 46,570 | $1.58 | $73,580.60 | (2%) 2.41M to 2.36M | |
| 01-Mar-24 5:49 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 29-Feb-24 | Sale | 8,661 | $1.58 | $13,684.40 | (1%) 715.59K to 706.93K | |
| 29-Feb-24 6:03 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-24 | Sale (Planned) | 7,411 | $1.52 | $11,264.70 | (1%) 676.64K to 669.23K | |
| 29-Feb-24 6:00 PM View: | Butler John P. CEO and President Director | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-24 | Sale | 37,733 | $1.52 | $57,354.20 | (2%) 2.45M to 2.41M | |
| 29-Feb-24 6:02 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-24 | Sale | 10,744 | $1.52 | $16,330.90 | (1%) 726.34K to 715.59K | |
| 29-Feb-24 6:01 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-24 | Sale (Planned) | 8,367 | $1.52 | $12,717.80 | (1%) 711.38K to 703.01K | |
| 02-Feb-24 4:10 PM View: | Butler John P. CEO and President Director | Akebia Therapeutics, Inc. (AKBA) | 01-Feb-24 | Sale | 46,489 | $1.68 | $78,101.50 | (2%) 2.5M to 2.45M | |
| 02-Feb-24 4:10 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 01-Feb-24 | Sale | 24,311 | $1.68 | $40,842.50 | (3%) 735.69K to 711.38K | |
| 02-Feb-24 4:11 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 149,300 | -- | -- | 26% 577.04K to 726.34K | |
| 02-Feb-24 4:10 PM View: | Snow Ellen SVP, CFO and Treasurer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 149,300 | -- | -- | 40% 370.0K to 519.3K | |
| 02-Feb-24 4:10 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 202,200 | -- | -- | 38% 533.49K to 735.69K | |
| 02-Feb-24 4:11 PM View: | Malabre Richard C Chief Accounting Officer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 223,950 | -- | -- | 100% 0 to 223.95K | |
| 02-Feb-24 4:10 PM View: | Butler John P. CEO and President Director | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 603,500 | -- | -- | 32% 1.89M to 2.5M | |
| 02-Feb-24 4:11 PM View: | Grund Nicholas Chief Commercial Officer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 303,300 | -- | -- | 100% 0 to 303.3K | |
| 02-Feb-24 4:10 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 31-Jan-24 | Grant | 149,300 | -- | -- | 28% 527.34K to 676.64K | |
| 09-May-24 5:27 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 25-Aug-23 | Sale | 27,000 | $1.15 | $31,050.00 | (4%) 695.84K to 668.84K | |
| 01-Aug-23 4:35 PM View: | Snow Ellen SVP, CFO and Treasurer | Akebia Therapeutics, Inc. (AKBA) | 31-Jul-23 | Grant | 370,000 | -- | -- | 100% 0 to 370.0K | |
| 08-Jun-23 4:07 PM View: | Frieson Ron Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 219% 13.7K to 43.7K | |
| 08-Jun-23 4:07 PM View: | Gilman Steven C Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 53% 57.13K to 87.13K | |
| 08-Jun-23 4:07 PM View: | Wolf Myles Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 80% 37.68K to 67.68K | |
| 08-Jun-23 4:07 PM View: | Smith Cynthia Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 46% 65.23K to 95.23K | |
| 08-Jun-23 4:07 PM View: | Adams Adrian Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 29% 104.8K to 134.8K | |
| 08-Jun-23 4:08 PM View: | Rogers Michael W Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 45% 66.03K to 96.03K | |
| 08-Jun-23 4:08 PM View: | Zumwalt Leanne M Director | Akebia Therapeutics, Inc. (AKBA) | 06-Jun-23 | Grant | 30,000 | -- | -- | 219% 13.7K to 43.7K | |
| 25-May-23 9:01 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 25-May-23 | Sale | 63,186 | $1.22 | $77,270.20 | (11%) 587.53K to 524.34K | |
| 25-May-23 9:01 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 25-May-23 | Sale | 95,478 | $1.22 | $116,760.00 | (14%) 669.51K to 574.04K | |
| 25-May-23 9:01 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 24-May-23 | Grant | 200,000 | -- | -- | 52% 387.53K to 587.53K | |
| 25-May-23 9:01 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 24-May-23 | Grant | 200,000 | -- | -- | 43% 469.51K to 669.51K | |
| 18-May-23 6:19 PM View: | Spellman David A SVP, CFO and Treasurer | Akebia Therapeutics, Inc. (AKBA) | 16-May-23 | Sale | 63,567 | $1.07 | $67,889.60 | (12%) 510.05K to 446.48K | |
| 18-May-23 6:20 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 16-May-23 | Sale | 63,567 | $1.07 | $67,889.60 | (11%) 594.05K to 530.49K | |
| 16-May-23 4:10 PM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 12-May-23 | Grant | 100,000 | -- | -- | 35% 287.53K to 387.53K | |
| 16-May-23 4:09 PM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 12-May-23 | Grant | 200,000 | -- | -- | 74% 269.51K to 469.51K | |
| 03-Mar-23 8:01 AM View: | Hadas Nicole R. SVP, Chief Legal Officer | Akebia Therapeutics, Inc. (AKBA) | 01-Mar-23 | Sale | 13,034 | $0.88 | $11,437.30 | (4%) 300.56K to 287.53K | |
| 03-Mar-23 8:01 AM View: | Butler John P. CEO and President Director | Akebia Therapeutics, Inc. (AKBA) | 01-Mar-23 | Sale | 91,868 | $0.88 | $80,614.20 | (5%) 1.98M to 1.89M | |
| 03-Mar-23 8:01 AM View: | Dahan Michel SVP, Chief Operating Officer | Akebia Therapeutics, Inc. (AKBA) | 01-Mar-23 | Sale | 20,412 | $0.88 | $17,911.50 | (7%) 289.93K to 269.51K | |
| 03-Mar-23 8:01 AM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 01-Mar-23 | Sale | 14,123 | $0.88 | $12,392.90 | (2%) 608.18K to 594.05K | |
| 03-Mar-23 8:00 AM View: | Spellman David A SVP, CFO and Treasurer | Akebia Therapeutics, Inc. (AKBA) | 01-Mar-23 | Sale | 7,210 | $0.88 | $6,326.77 | (1%) 517.26K to 510.05K | |
| 01-Mar-23 4:06 PM View: | Burke Steven Keith SVP, Chief Medical Officer | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-23 | Sale | 7,539 | $0.81 | $6,130.71 | (1%) 615.72K to 608.18K | |
| 01-Mar-23 4:05 PM View: | Spellman David A SVP, CFO and Treasurer | Akebia Therapeutics, Inc. (AKBA) | 27-Feb-23 | Sale | 7,539 | $0.81 | $6,130.71 | (1%) 524.8K to 517.26K |
